Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||B02 + Veliparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|B02||RAD51 Inhibitor 4||B02 is a small molecule inhibitor of RAD51 with the potential to block homologous recombination repair thereby increasing the sensitivity of therapies that induce DNA damage (PMID: 25401086).|
|Veliparib||ABT-888||PARP Inhibitor (Pan) 22||Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which inhibits DNA repair and induces lethality in homologous recombination deficient cells, and may enhance the sensitivity of chemotherapeutic agents (PMID: 26251615, PMID: 31074636, PMID: 32452601).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||B02 + Veliparib||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of B02 resulted in increased sensitivity to Veliparib (ABT-888), in a multiple myeloma cell line in culture, leading decreased cell viability (PMID: 26719576).||26719576|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|